Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2004

Conditions
Hemophilia B
Interventions
GENETIC

Adeno-Associated Viral with Human Factor IX

Trial Locations (3)

15213

The Hemophilia Center of Western Pennsylvania, Pittsburgh

19104

The Children's Hospital of Philadelphia, Philadelphia

94305

Stanford University, Palo Alto

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

The Hemophilia Center of Western Pennsylvania

OTHER

collaborator

University of Washington

OTHER

collaborator

The University of Texas Health Science Center, Houston

OTHER

collaborator

University of Campinas, Brazil

OTHER

collaborator

Christian Medical College, Vellore, India

OTHER

collaborator

Royal Prince Alfred Hospital, Sydney, Australia

OTHER

lead

Avigen

INDUSTRY

NCT00076557 - Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B | Biotech Hunter | Biotech Hunter